Anticoagulation Management for Cardioversion with Eliquis (Apixaban)

General Principles for Anticoagulation with Cardioversion

The American College of Cardiology recommends that Eliquis (apixaban) should not be held before cardioversion for atrial fibrillation, and therapeutic anticoagulation with Eliquis should be continued for at least 3 weeks before and 4 weeks after cardioversion for patients with AF duration >48 hours or unknown duration 1, 2
The American College of Chest Physicians suggests that this recommendation applies to both electrical and pharmacological cardioversion 2
The American Heart Association considers NOACs like apixaban as effective and safe alternatives to warfarin for patients undergoing cardioversion 3

For patients with AF duration <48 hours and a CHA₂DS₂-VASc score ≥2 in men or ≥3 in women, anticoagulation with apixaban should be administered before cardioversion and continued afterward, according to the American Heart Association 3
For patients with AF duration <48 hours and a CHA₂DS₂-VASc score of 0 in men or 1 in women, anticoagulation may be considered before cardioversion without the need for post-cardioversion oral anticoagulation, as recommended by the American Heart Association 3

In patients requiring immediate cardioversion due to hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least 4 weeks after the procedure, according to the American College of Cardiology and the American Heart Association 1, 3
The American College of Chest Physicians recommends that initiation of anticoagulation should not delay emergency intervention 4
For patients with AF >48 hours who have not been anticoagulated for the preceding 3 weeks, a TEE-guided approach is reasonable, as suggested by the American Heart Association 3

The decision about continuing anticoagulation beyond 4 weeks should be based on the patient's thromboembolic risk profile (CHA₂DS₂-VASc score) and bleeding risk profile, not on the success of cardioversion, according to the American College of Cardiology and the American Heart Association 1, 3
The European Heart Journal explains that cardioversion can cause transient mechanical dysfunction of the left atrium ("stunning"), which may lead to thrombus formation even after successful restoration of sinus rhythm 5
The European Heart Journal also notes that continuous anticoagulation through the cardioversion period protects against thromboembolic events 5

The American College of Chest Physicians warns against discontinuing anticoagulation immediately after successful cardioversion, and recommends continuing for at least 4 weeks 2, 3
The American College of Cardiology advises against delaying emergency cardioversion to achieve therapeutic anticoagulation in hemodynamically unstable patients 1, 4
The European Heart Journal cautions that assuming atrial flutter carries no risk of thromboembolism is incorrect, and requires the same anticoagulation approach as AF 5, 6

The European Society of Cardiology recommends that all patients undergoing cardioversion require therapeutic anticoagulation for at least 4 weeks after the procedure, regardless of baseline stroke risk or CHA₂DS₂-VASc score, due to the phenomenon of atrial stunning that occurs after cardioversion 7, 8, 9
98% of thromboembolic events after cardioversion occur within the first 10 days, with the majority happening within the first 3 days, making this early post-cardioversion period particularly high-risk 7, 10
The American College of Chest Physicians recommends initiating therapeutic anticoagulation immediately if not already started, either with a NOAC like apixaban or rivaroxaban, or warfarin targeting INR 2-3, for a minimum of 4 weeks post-cardioversion 8, 9

The European Heart Journal recommends beta blockers for rate control while awaiting cardiology follow-up, particularly because atrial fibrillation recurrence is common after cardioversion 7
Beta blockers help control ventricular rate if atrial fibrillation recurs before the cardiology appointment and provide symptomatic relief 7

The American College of Chest Physicians advises against discontinuing anticoagulation immediately after successful cardioversion, as atrial stunning persists for weeks despite return to sinus rhythm 8, 9
The European Society of Cardiology recommends not assuming young age or low CHA₂DS₂-VASc score eliminates the need for post-cardioversion anticoagulation, as the 4-week anticoagulation requirement applies to all patients regardless of baseline stroke risk 8, 9